Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Elaine Greer, Groton, CT (US); Stephen Anderson, Stonington, CT (US); Mark Maloney, East Lyme, CT (US); Shu Yu, Salem, CT (US); Ekaterina Albert, West Lafayette, IN (US); and Emily Rigsbee, West Lafayette, IN (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jul. 28, 2023, as Appl. No. 18/361,545.
Application 18/157,592 is a division of application No. 17/180,296, filed on Feb. 19, 2021, granted, now 11,566,006, issued on Jan. 31, 2023.
Application 16/886,622 is a division of application No. 16/818,863, filed on Mar. 13, 2020, granted, now 10,710,966, issued on Jul. 14, 2020.
Application 16/818,863 is a division of application No. 16/537,394, filed on Aug. 9, 2019, granted, now 10,590,087, issued on Mar. 17, 2020.
Application 18/361,545 is a continuation of application No. 18/157,592, filed on Jan. 20, 2023.
Application 17/180,296 is a continuation of application No. 16/886,622, filed on May 28, 2020, granted, now 10,941,118, issued on Mar. 9, 2021.
Prior Publication US 2023/0382872 A1, Nov. 30, 2023
1. A pharmaceutical composition comprising a solid form of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide or a salt thereof, wherein the solid form exhibits a loss of at least 8 wt % between about 60 and about 190° C. according to thermogravimetric analysis.